Amgen ($AMGN) is a leading biotechnology company with a diverse portfolio spanning oncology, immunology, cardiometabolic, and rare diseases. As a major player in the biopharmaceutical industry, Amgen faces competition from both large multinational pharmaceutical companies and specialized biotech firms. Understanding Amgen’s competitive landscape is crucial for investors, analysts, and industry observers. Below, we outline Amgen’s principal competitors and peers, followed by a comparative analysis and a summary table.
Key Competitors and Peers of Amgen
- Amgen, Inc. ($AMGN) – United States
- Merck & Co., Inc. ($MRK) – United States
- Biogen Inc. ($BIIB) – United States
- Regeneron Pharmaceuticals, Inc. ($REGN) – United States
- Bristol Myers Squibb Company ($BMY) – United States
- Pfizer Inc. ($PFE) – United States
- Gilead Sciences, Inc. ($GILD) – United States
- Eli Lilly and Company ($LLY) – United States
Competitive Comparison Table
| Company Name | Ticker | Key Product Lines (Selected) | Notable Competitive Overlap with Amgen | Subsector | Market Cap |
|---|---|---|---|---|---|
| Amgen, Inc. | $AMGN | Prolia, Repatha, Otezla, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, Nplate, TEZSPIRE, KYPROLIS, Vectibix | Drug Manufacturers - General | $199.20B | |
| Merck & Co., Inc. | $MRK | Keytruda, Gardasil, Januvia, Lynparza (alliance), Lenvima (alliance), Vaxneuvance, Welireg | Oncology (Keytruda vs. Vectibix), immunology-adjacent | Drug Manufacturers - General | $286.28B |
| Biogen Inc. | $BIIB | TECFIDERA, VUMERITY, AVONEX, TYSABRI, SPINRAZA, LEQEMBI, BENEPALI (biosimilar to ENBREL) | Biosimilars (BENEPALI vs. ENBREL) | Drug Manufacturers - General | $27.13B |
| Regeneron Pharmaceuticals | $REGN | EYLEA, Dupixent, Libtayo, Praluent, Kevzara, ARCALYST | Praluent vs. Repatha, Dupixent vs. TEZSPIRE, biosimilars | Biotechnology | $77.97B |
| Bristol Myers Squibb Company | $BMY | Opdivo, Orencia, Yervoy, Sotyktu, Eliquis, Revlimid, Pomalyst, Abraxane | Sotyktu vs. Otezla, Orencia vs. ENBREL, oncology, immunology | Drug Manufacturers - General | $122.78B |
| Pfizer Inc. | $PFE | Eliquis, Xeljanz, Enbrel (ex-US/Canada), Ibrance, biosimilars | Xeljanz vs. ENBREL, Enbrel (ex-US/Canada), biosimilars, oncology | Drug Manufacturers - General | $153.81B |
| Gilead Sciences, Inc. | $GILD | Biktarvy, Descovy, Veklury, Trodelvy, Yescarta, Tecartus | No direct head-to-head competition cited in retrieved evidence | Drug Manufacturers - General | $178.71B |
| Eli Lilly and Company | $LLY | Mounjaro, Trulicity, Taltz, Erbitux, Verzenio, Jaypirca, Omvoh | Taltz vs. Otezla, Erbitux vs. Vectibix, oncology, immunology | Drug Manufacturers - General | $884.72B |
Amgen vs. Competitor Comparisons
Amgen vs. Merck ($MRK)
- Both companies have significant oncology portfolios. Amgen’s Vectibix directly competes with Merck’s Keytruda in the U.S. Merck’s broad product base also covers vaccines and hospital care, while Amgen is more focused on biologics and specialty therapeutics.
Amgen vs. Biogen ($BIIB)
- The most direct overlap is in biosimilars, with Biogen’s BENEPALI (etanercept biosimilar) competing with Amgen’s ENBREL. Biogen’s core focus is neurology and rare diseases, while Amgen’s is broader.
Amgen vs. Regeneron ($REGN)
- Regeneron’s Praluent competes with Amgen’s Repatha in cholesterol management. Dupixent (Regeneron/Sanofi) is a key competitor to Amgen’s TEZSPIRE in respiratory diseases. Regeneron also competes in biosimilars (Pavblu vs. EYLEA).
Amgen vs. Bristol Myers Squibb ($BMY)
- Overlap in immunology and oncology is significant. BMS’s Sotyktu competes with Otezla, Orencia with ENBREL, and several oncology products compete with Amgen’s KYPROLIS.
Amgen vs. Pfizer ($PFE)
- Pfizer’s Xeljanz competes with ENBREL, and Pfizer markets Enbrel outside the U.S. and Canada. Both companies have biosimilar portfolios and compete in oncology and immunology.
Amgen vs. Gilead ($GILD)
- No explicit direct product competition is cited in the retrieved evidence, but both are large biopharma companies with broad portfolios.
Amgen vs. Eli Lilly ($LLY)
- Lilly’s Taltz competes with Otezla, and Erbitux (with Merck KGaA) competes with Vectibix. Both companies have strong oncology and immunology franchises.
Conclusion
Amgen ($AMGN) operates in a highly competitive environment, facing direct and indirect competition from major pharmaceutical and biotechnology companies. Its principal competitors include Merck, Biogen, Regeneron, Bristol Myers Squibb, Pfizer, Gilead, and Eli Lilly. The competitive dynamics are shaped by overlapping product portfolios in oncology, immunology, biosimilars, and specialty therapeutics. Understanding these relationships is essential for assessing Amgen’s market position and future growth prospects.